Caribou Biosciences, Inc. (CRBU)
| Market Cap | 130.79M -38.9% |
| Revenue (ttm) | 10.04M +10.0% |
| Net Income | -103.40M |
| EPS | -1.08 |
| Shares Out | 107.21M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 679,481 |
| Open | 1.270 |
| Previous Close | 1.270 |
| Day's Range | 1.220 - 1.285 |
| 52-Week Range | 1.220 - 3.535 |
| Beta | 2.31 |
| Analysts | Strong Buy |
| Price Target | 11.86 (+872.13%) |
| Est. Earnings | Nov 11, 2026 |
About CRBU
Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCM... [Read more]
Financial Performance
In 2025, Caribou Biosciences's revenue was $11.16 million, an increase of 11.66% compared to the previous year's $9.99 million. Losses were -$148.13 million, -0.66% less than in 2024.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for CRBU stock is "Strong Buy." The 12-month stock price target is $11.86, which is an increase of 872.13% from the latest price.
News
Caribou Biosciences reports Q2 EPS (24c), consensus (31c)
Reports Q2 revenue $1.5M, consensus $2.25M. “At Caribou, we are redefining what patients and physicians should expect from allogeneic CAR-T cell therapy,” said Rachel Haurwitz, president and CEO of Ca...
Caribou Biosciences price target lowered to $5 from $6 at BofA
BofA lowered the firm’s price target on Caribou Biosciences (CRBU) to $5 from $6 and keeps a Buy rating on the shares. The firm adjusted targets for several names in…
Caribou Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
-- ANTLER phase 1 data presented at EHA 2026 reinforce vispa-cel safety, efficacy, and durability are on par with approved autologous CAR-T cell therapies and that vispa-cel has the potential to overc...
Caribou Biosciences Quarterly report: Q2 2026
Caribou Biosciences has published its Q2 2026 quarterly earnings report on August 13, 2026.
Caribou Biosciences Earnings release: Q2 2026
Caribou Biosciences released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Caribou Biosciences Transcript: H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
The discussion highlighted pivotal-ready vispa-cel and promising CB-011 data, both leveraging a highly specific genome editing platform to address access and efficacy gaps in hematologic malignancies. Vispa-cel offers rapid, off-the-shelf delivery and strong safety, while CB-011 shows durable responses in late-line myeloma.
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz,...
Caribou Biosciences Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and a proposed officer exculpation amendment, which was not approved. All other proposals passed, and no questions were raised by stockholders. Voting results will be reported to the SEC.
Caribou Biosciences presents ANTLER trial results at EHA
Caribou Biosciences (CRBU) announced that vispa-cel, its off-the-shelf CD19-targeted CAR-T cell therapy, produced durable long-term responses in patients enrolled in the ANTLER phase 1 clinical trial ...
Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026
-- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient admi...
Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting
-- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in ≥CR at 15 months -- -- Case st...
Caribou Biosciences Slides: Corporate presentation
Caribou Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on June 10, 2026.
Caribou Biosciences Proxy statement: Proxy filing
Caribou Biosciences filed a proxy statement on June 5, 2026, providing details for shareholder voting and corporate governance matters.
Caribou Biosciences Transcript: Jefferies Global Healthcare Conference 2026
Two off-the-shelf CAR T programs are advancing: vispa-cel (pivotal-ready for lymphoma) and CB-011 (phase I for myeloma). The pivotal ANTLER III study targets patients lacking access to autologous CAR T, with rapid timelines and global reach. Key data updates are expected at EHA and by year-end.
Caribou Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
BERKELEY, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, ...
Caribou Biosciences Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference
Two allogeneic CAR T programs are advancing, with vispa-cel showing efficacy and safety comparable to autologous CAR T and poised for a pivotal phase III trial. CB-011 demonstrated strong early results in multiple myeloma, with expansion data expected later this year.
Caribou Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference
BERKELEY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced that Caribou's ma...
Caribou Biosciences Transcript: Bank of America Global Healthcare Conference 2026
Two off-the-shelf CAR-T therapies are advancing, with vispa-cel showing durable, auto CAR T-like responses in lymphoma and CB-011 exceeding bispecific benchmarks in multiple myeloma. Phase III for vispa-cel targets patients ineligible for auto CAR T, with broad commercial and manufacturing scalability. Key data updates are expected at EHA and year-end.
Caribou Biosciences to Highlight Vispa-cel and CB-011 Programs During Oral Presentations at the 2026 European Hematology Association (EHA) Annual Meeting
BERKELEY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced two abstracts hav...
Caribou Biosciences price target raised to $11 from $9 at H.C. Wainwright
H.C. Wainwright analyst Robert Burns raised the firm’s price target on Caribou Biosciences (CRBU) to $11 from $9 and keeps a Buy rating on the shares post the Q1 report.
Caribou Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
-- Achieved alignment with FDA on pivotal ANTLER-3 trial design for vispa-cel in 2L LBCL -- -- Longer follow up on vispa-cel phase 1 clinical data expected at medical conference in 2026 -- -- CaMMoufl...
Caribou Biosciences Quarterly report: Q1 2026
Caribou Biosciences has published its Q1 2026 quarterly earnings report on May 7, 2026.
Caribou Biosciences Earnings release: Q1 2026
Caribou Biosciences released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Caribou Biosciences to Participate in the BofA Securities 2026 Health Care Conference
BERKELEY, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, ...
Caribou Biosciences Proxy statement: Proxy filing
Caribou Biosciences filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.